Literature DB >> 24442603

A suspicion index for early diagnosis and treatment of cerebrotendinous xanthomatosis.

Andrea Mignarri1, Gian Nicola Gallus, Maria Teresa Dotti, Antonio Federico.   

Abstract

BACKGROUND: Cerebrotendinous xanthomatosis (CTX) is an autosomal recessive lipid storage disorder characterized by a heterogeneous presentation and a broad spectrum of clinical manifestations. Since early diagnosis and replacement therapy with chenodeoxycholic acid can prevent clinical deterioration, our aim was to develop a diagnostic tool to identify and treat CTX patients at an initial stage of the disease.
METHODS: We devised a suspicion index, composed of weighted scores assigned to indicators such as family history characteristics and common systemic and neurological features, on the basis of a pooled analysis of selected international CTX series. The indicators were classified as very strong (score 100), strong (50) or moderate (25). The suspicion index was then applied retrospectively to our CTX population.
RESULTS: Early systemic signs such as cataract, diarrhea and neonatal cholestatic jaundice were considered strong indicators, together with neurological features such as intellectual impairment, psychiatric disturbances, ataxia, spastic paraparesis and dentate nuclei abnormalities at MRI. Tendon xanthomas were regarded as very strong indicators, as was an affected sibling. A total score ≥ 100 warranted serum cholestanol assessment. Elevated cholestanol or a total score ≥ 200, with one very strong or four strong indicators, warranted CYP27A1 gene analysis. In our patients, age at diagnosis was 35.5 ± 11.8 years (mean ± standard deviation), whereas with the diagnostic tool it became 10.6 ± 9.8 years (p < 0.01).
CONCLUSIONS: Our suspicion index provides a simple and inexpensive diagnostic tool allowing diagnosis and treatment of CTX before neurological disability occurs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24442603     DOI: 10.1007/s10545-013-9674-3

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  39 in total

1.  Cerebrotendinous xanthomatosis with progressive cerebellar vacuolation : six-year MRI follow-up.

Authors:  Andrea Mignarri; Maria Teresa Dotti; Marina Del Puppo; Gian Nicola Gallus; Antonio Giorgio; Alfonso Cerase; Lucia Monti
Journal:  Neuroradiology       Date:  2012-03-15       Impact factor: 2.804

2.  Children with cataract and chronic diarrhoea: cerebrotendinous xanthomatosis.

Authors:  J R M Cruysberg
Journal:  J Inherit Metab Dis       Date:  2009-03-09       Impact factor: 4.982

3.  Mutation in the sterol 27-hydroxylase gene associated with fatal cholestasis in infancy.

Authors:  Sara von Bahr; Ingemar Björkhem; Ferdinand Van't Hooft; Gunvor Alvelius; Antal Nemeth; Jan Sjövall; Björn Fischler
Journal:  J Pediatr Gastroenterol Nutr       Date:  2005-04       Impact factor: 2.839

4.  Neurophysiological study in cerebrotendinous xanthomatosis.

Authors:  Belen Pilo; Gema de Blas; Maria Jesus Sobrido; Carmen Navarro; Francisco Grandas; Francisco J Barrero; Miguel Angel Moya; Adriano Jimenez-Escrig
Journal:  Muscle Nerve       Date:  2011-04       Impact factor: 3.217

5.  Increased concentrations of cholestanol and apolipoprotein B in the cerebrospinal fluid of patients with cerebrotendinous xanthomatosis. Effect of chenodeoxycholic acid.

Authors:  G Salen; V Berginer; V Shore; I Horak; E Horak; G S Tint; S Shefer
Journal:  N Engl J Med       Date:  1987-05-14       Impact factor: 91.245

6.  Neurological outcome in cerebrotendinous xanthomatosis treated with chenodeoxycholic acid: early versus late diagnosis.

Authors:  Gilad Yahalom; Rakefet Tsabari; Noa Molshatzki; Lilach Ephraty; Hofit Cohen; Sharon Hassin-Baer
Journal:  Clin Neuropharmacol       Date:  2013 May-Jun       Impact factor: 1.592

7.  Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid.

Authors:  V M Berginer; G Salen; S Shefer
Journal:  N Engl J Med       Date:  1984-12-27       Impact factor: 91.245

Review 8.  Atypical parkinsonism and cerebrotendinous xanthomatosis: report of a family with corticobasal syndrome and a literature review.

Authors:  Ignacio Rubio-Agusti; Maja Kojovic; Mark J Edwards; Elaine Murphy; Hoskote S Chandrashekar; Robin H Lachmann; Kailash P Bhatia
Journal:  Mov Disord       Date:  2012-11-02       Impact factor: 10.338

9.  Prospective treatment of cerebrotendinous xanthomatosis with cholic acid therapy.

Authors:  Germaine Pierre; Kenneth Setchell; Jacqueline Blyth; Mary Anne Preece; Anupam Chakrapani; Patrick McKiernan
Journal:  J Inherit Metab Dis       Date:  2008-12-27       Impact factor: 4.982

10.  Chronic diarrhea and juvenile cataracts: think cerebrotendinous xanthomatosis and treat.

Authors:  Vladimir M Berginer; Bella Gross; Khayat Morad; Nechama Kfir; Siman Morkos; Salameh Aaref; Tzipora C Falik-Zaccai
Journal:  Pediatrics       Date:  2009-01       Impact factor: 7.124

View more
  37 in total

1.  Evaluation of cholesterol metabolism in cerebrotendinous xanthomatosis.

Authors:  Andrea Mignarri; Alessandro Magni; Marina Del Puppo; Gian Nicola Gallus; Ingemar Björkhem; Antonio Federico; Maria Teresa Dotti
Journal:  J Inherit Metab Dis       Date:  2015-07-08       Impact factor: 4.982

2.  Screening for cerebrotendinous xanthomatosis.

Authors:  James J Pitt; Heidi Peters
Journal:  J Inherit Metab Dis       Date:  2014-09-19       Impact factor: 4.982

3.  Newborn screening for cerebrotendinous xanthomatosis is the solution for early identification and treatment.

Authors:  Andrea E DeBarber; Limor Kalfon; Ayalla Fedida; Vered Fleisher Sheffer; Shani Ben Haroush; Natalia Chasnyk; Efrat Shuster Biton; Hanna Mandel; Krystal Jeffries; Eric S Shinwell; Tzipora C Falik-Zaccai
Journal:  J Lipid Res       Date:  2018-08-22       Impact factor: 5.922

4.  Clinical and molecular genetic features of cerebrotendinous xanthomatosis patients in Chinese families.

Authors:  Chen Chen; Yue Zhang; Hui Wu; Yi-Min Sun; Ye-Hua Cai; Jian-Jun Wu; Jian Wang; Ling-Yun Gong; Zheng-Tong Ding
Journal:  Metab Brain Dis       Date:  2017-06-17       Impact factor: 3.584

5.  Cerebrotendinous Xanthomatosis Presenting with Infantile Spasms and Intellectual Disability.

Authors:  Austin Larson; James D Weisfeld-Adams; Tim A Benke; Penelope E Bonnen
Journal:  JIMD Rep       Date:  2016-11-18

6.  Nationwide survey on cerebrotendinous xanthomatosis in Japan.

Authors:  Yoshiki Sekijima; Shingo Koyama; Tsuneaki Yoshinaga; Masayoshi Koinuma; Yuji Inaba
Journal:  J Hum Genet       Date:  2018-01-10       Impact factor: 3.172

7.  The spectrum of magnetic resonance findings in cerebrotendinous xanthomatosis: redefinition and evidence of new markers of disease progression.

Authors:  Andrea Mignarri; Maria Teresa Dotti; Antonio Federico; Nicola De Stefano; Marco Battaglini; Irene Grazzini; Paolo Galluzzi; Lucia Monti
Journal:  J Neurol       Date:  2017-03-21       Impact factor: 4.849

8.  Treatment with chenodeoxycholic acid in cerebrotendinous xanthomatosis: clinical, neurophysiological, and quantitative brain structural outcomes.

Authors:  Maria Del Mar Amador; Marion Masingue; Rabab Debs; Foudil Lamari; Vincent Perlbarg; Emmanuel Roze; Bertrand Degos; Fanny Mochel
Journal:  J Inherit Metab Dis       Date:  2018-03-20       Impact factor: 4.982

9.  The role of dentate nuclei in human oculomotor control: insights from cerebrotendinous xanthomatosis.

Authors:  Francesca Rosini; Elena Pretegiani; Andrea Mignarri; Lance M Optican; Valeria Serchi; Nicola De Stefano; Marco Battaglini; Lucia Monti; Maria T Dotti; Antonio Federico; Alessandra Rufa
Journal:  J Physiol       Date:  2017-03-14       Impact factor: 5.182

10.  Apparent underdiagnosis of Cerebrotendinous Xanthomatosis revealed by analysis of ~60,000 human exomes.

Authors:  Vivek Appadurai; Andrea DeBarber; Pei-Wen Chiang; Shailendra B Patel; Robert D Steiner; Charles Tyler; Penelope E Bonnen
Journal:  Mol Genet Metab       Date:  2015-10-26       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.